Overview

Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining carboplatin and topotecan in treating patients with relapsed acute myelogenous leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carboplatin
Topotecan
Criteria
DISEASE CHARACTERISTICS: Previously established diagnosis of acute myelogenous leukemia:
Failure to achieve a complete remission with initial induction regimen First relapse within
1 year of initial complete remission Failure to achieve complete remission with one or two
courses of reinduction therapy at first relapse Second relapse after no more than two
different induction regimens Chemotherapy-related leukemia with unfavorable cytogenetics No
active CNS leukemia Not eligible for allogeneic bone marrow transplant from related donor

PATIENT CHARACTERISTICS: Age: 18 to 74 Performance status: ECOG 0-2 Life expectancy: At
least 4 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than upper limit
of normal (ULN) (unless elevation due to AML) Renal: Creatinine no greater than 0.3 mg/dL
above ULN Cardiovascular: No myocardial infarction within the past 3 months No congestive
heart failure No poorly controlled cardiac arrhythmia Other: Not pregnant or nursing
Fertile patients must use adequate contraception No psychosis No active systemic infections

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Recovered from the
toxic effects of previous chemotherapy At least 3 days since hydroxyurea Endocrine therapy:
Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior or
concurrent aminoglycosides or amphotericin B within past 7 days